Share
People with type 2 diabetes on a high-fat, low-carbohydrate diet may have a better chance of reversing their diabetes than those on a low-fat diet, according to a small study published in the Journal of the Endocrine Society. Type 2 diabetes is a disease where the beta cells in the pancreas cannot secrete enough insulin...
Share
A new prospective study has found that initiating continuous glucose monitoring (CGM) at the point of hospital discharge is associated with significantly improved glycemic control and may halve the risk of hospital readmission for patients with type 2 diabetes. The research, published in Journal of the Endocrine Society, suggests that providing patients with real-time data...
Share
Eli Lilly’s “Ozempic-in-a-pill” candidate just cleared its most significant clinical hurdle to date. The pharmaceutical giant announced that its experimental once-daily pill, orforglipron, met all primary and secondary endpoints in two pivotal Phase 3 trials: ACHIEVE-2 and ACHIEVE-5. Data indicate that this oral treatment provides superior glycemic control compared to both a standard SGLT-2 inhibitor...
Share
New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both. The study (the SURPASS-PEDS trial), led...
Share
A recently published Scientific Statement sheds light on new and improved treatment options for type 1 diabetes. Endocrine News speaks with first author Aaron W. Michels, MD, about the Statement’s implications and why this is an exciting time in type 1 diabetes research. In July, the Endocrine Society published a Scientific Statement that highlights potential...
Share
A new study from a poison control center in Alabama offers a reassuring perspective on the rising number of calls related to popular GLP-1 receptor agonists, such as Ozempic and Wegovy. While exposures to these medications have increased significantly over the past two decades, the research suggests many cases are accidental, associated with mild symptoms,...
Share
As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — such as semaglutide (Ozempic, Wegovy) — gain traction for treating diabetes and promoting weight loss, a new concern is emerging: Are older adults at risk of losing too much muscle? An editorial in Annals of Internal Medicine warns that these popular drugs may exacerbate sarcopenia — the...
Share
New Endocrine Society and European Endocrine Society guidelines provide a much-needed update Making its debut at ENDO 2025, “Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline” has been long anticipated. For the first time, clinicians will have a definitive guide on treating these patients that now includes the...
